Seaport Therapeutics, Inc. — Q3 2026 Form 10-Q
Reporting period: Three and nine months ended September 30, 2026; filed November 2, 2026. Seaport is a clinical-stage therapeutics company developing medicines for neuropsychiatric disorders using its Glyph platform. It has no product-sales revenue and does not expect near-term sales.
Financial highlights
Amounts in $ millions, except per-share data. No operating margins are meaningful because the company has no revenue.
| Metric | Q3 2026 | Q3 2025 | Nine months 2026 | Nine months 2025 |
|---|---|---|---|---|
| Revenue | None | None | None | None |
| Research and development expense | $23.9 | $20.5 | $69.9 | $44.4 |
| General and administrative expense | $6.5 | $5.0 | $53.8 | $15.7 |
| Total operating expenses | $30.3 | $25.4 | $123.7 | $60.1 |
| Net loss | $26.4 | $22.5 | $114.4 | $50.7 |
| Net loss per share, basic and diluted | $0.49 | $9.43 | $3.72 | $21.53 |
| Operating cash used | — | — | $69.0 | $51.3 |
- At September 30, 2026, cash and cash equivalents were $61.6 million and investments were $342.2 million, totaling $403.8 million. Total assets were $417.6 million; current liabilities were $17.1 million. The company reported no debt; lease liabilities totaled $4.7 million.
- For the first nine months, financing activities provided $240.0 million, primarily from the May 2026 IPO. Net IPO proceeds were approximately $238.4 million. Cash, cash equivalents and restricted cash ended the period at $62.0 million; much of the company’s liquidity is held in U.S. Treasury investments.
- Accumulated deficit was $228.5 million. Stockholders’ equity was $397.5 million, compared with a $92.5 million deficit at December 31, 2025, reflecting the IPO and conversion of preferred shares to common stock.
Changes and notable items
- Q3 net loss increased $3.9 million year over year as operating expenses rose $4.9 million, partly offset by $1.1 million more other income, primarily investment interest.
- Nine-month R&D expense rose $25.5 million, mainly from advancing GlyphAllo’s Phase 2b BUOY-1 trial and GlyphAgo’s development. Management attributed a $15.5 million increase to GlyphAllo and a $5.2 million increase to GlyphAgo.
- Nine-month G&A expense increased $38.1 million. The largest driver was $35.7 million of additional non-cash stock-based compensation, including fully vested IPO-related awards and accelerated vesting. Total stock-based compensation was $41.9 million for the nine months.
- Available-for-sale investments had $2.0 million of net unrealized losses at September 30, recorded in other comprehensive loss; no securities were in an unrealized loss position for more than twelve months.
Outlook, programs and risks
- Management estimates that September 30 cash, cash equivalents and investments can fund operations into 2029 under its current operating plan. The filing also states that existing resources are expected to cover at least twelve months from issuance of the financial statements. These estimates depend on assumptions and development costs and timing may differ; the company expects substantial future expenses and says it will need additional capital.
- GlyphAllo: Phase 2b BUOY-1 in major depressive disorder is underway; topline results are expected in the first half of 2027. Seaport reported positive topline results in September 2026 from a Phase 1 driving simulation trial: evening dosing did not impair next-morning driving performance versus placebo.
- GlyphAgo: Seaport reported Phase 1 findings of increased bioavailability and lower pharmacokinetic variability versus unmodified agomelatine, with favorable reported tolerability and no liver-related adverse events in the studies described. The first patient was dosed in a Phase 2a GAD/sleep-disturbance trial in October 2026; topline data are expected in early 2028. A Phase 2/3 GAD trial is expected to begin in the first half of 2027, with topline data expected by year-end 2028.
- Glyph2BLSD remains in nonclinical development; first-in-human-enabling studies are expected to be completed by year-end 2027.
- Key risks include clinical efficacy, safety and regulatory uncertainty; enrollment and trial delays; reliance on contract manufacturers, CROs and licensed intellectual property; possible controlled-substance regulation for certain candidates; competition; and the need for additional financing. Management reported effective disclosure controls and no material adverse legal proceedings.
Important facts for investors to verify
- Whether BUOY-1 progresses on schedule and whether its results support the planned development path.
- GlyphAgo’s Phase 2a and planned Phase 2/3 timing, and the basis for its stated safety and exposure findings.
- The assumptions behind the projected cash runway into 2029, quarterly cash burn and timing or terms of any future financing.
- The extent to which IPO-related non-cash compensation affects comparisons of G&A expense and future reported losses.
- Potential dilution from outstanding options: 12.3 million options were outstanding at September 30, 2026; the filing reports 53.5 million common shares outstanding as of October 27, 2026.